lorazepam has been researched along with Basal Ganglia Diseases in 10 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to examine the efficacy and side effects of haloperidol, chlorpromazine, and lorazepam for the treatment of the symptoms of delirium in adult AIDS patients in a randomized, double-blind, comparison trial." | 9.08 | A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. ( Breitbart, W; Corbera, K; Derevenco, M; Grau, C; Jacobson, P; Lund, S; Marotta, R; Platt, MM; Raymond, S; Weisman, H, 1996) |
| " Hyperactivity, impulsivity, and inattention improved with lorazepam, suggesting that the attention-deficit/hyperactivity disorder symptoms could be manifestations of catatonia." | 7.73 | PANDAS with catatonia: a case report. Therapeutic response to lorazepam and plasmapheresis. ( Ahmed, AA; Balamuth, N; Dell, ML; Elia, J; Friedman, DF; Pati, S; Zimmerman, RA, 2005) |
| "The purpose of this study was to examine the efficacy and side effects of haloperidol, chlorpromazine, and lorazepam for the treatment of the symptoms of delirium in adult AIDS patients in a randomized, double-blind, comparison trial." | 5.08 | A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. ( Breitbart, W; Corbera, K; Derevenco, M; Grau, C; Jacobson, P; Lund, S; Marotta, R; Platt, MM; Raymond, S; Weisman, H, 1996) |
| " Hyperactivity, impulsivity, and inattention improved with lorazepam, suggesting that the attention-deficit/hyperactivity disorder symptoms could be manifestations of catatonia." | 3.73 | PANDAS with catatonia: a case report. Therapeutic response to lorazepam and plasmapheresis. ( Ahmed, AA; Balamuth, N; Dell, ML; Elia, J; Friedman, DF; Pati, S; Zimmerman, RA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yatham, LN | 1 |
| Grossman, F | 1 |
| Augustyns, I | 1 |
| Vieta, E | 1 |
| Ravindran, A | 1 |
| Lejeune, J | 1 |
| Larmo, I | 1 |
| Chrzanowski, W | 1 |
| Witte, R | 1 |
| Karavatos, A | 1 |
| Schreiner, A | 1 |
| Lex, A | 1 |
| Medori, R | 1 |
| Elia, J | 1 |
| Dell, ML | 1 |
| Friedman, DF | 1 |
| Zimmerman, RA | 1 |
| Balamuth, N | 1 |
| Ahmed, AA | 1 |
| Pati, S | 1 |
| Kwon, P | 1 |
| Lefkowitz, W | 1 |
| Moleman, P | 1 |
| Schmitz, PJ | 1 |
| Ladee, GA | 1 |
| Krstenansky, PM | 1 |
| Petree, J | 1 |
| Long, G | 1 |
| Breitbart, W | 1 |
| Marotta, R | 1 |
| Platt, MM | 1 |
| Weisman, H | 1 |
| Derevenco, M | 1 |
| Grau, C | 1 |
| Corbera, K | 1 |
| Raymond, S | 1 |
| Lund, S | 1 |
| Jacobson, P | 1 |
| Duggal, HS | 1 |
| Chouinard, G | 1 |
| Craig, JB | 1 |
| Powell, BL | 1 |
| White, DR | 1 |
| Capizzi, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder[NCT00250367] | Phase 3 | 151 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| Comparison of Oral Risperdal in Combination With Oral Lorazepam vs Standard Care Including Initial Conventional Neuroleptic IM Treatment, in Acute Schizophrenic Patients[NCT00249171] | Phase 4 | 226 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for lorazepam and Basal Ganglia Diseases
| Article | Year |
|---|---|
Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial.
Topics: Adult; Aged; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Brief | 2003 |
Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aggression; Antipsy | 2004 |
A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients.
Topics: Adult; AIDS Dementia Complex; Basal Ganglia Diseases; Chlorpromazine; Delirium; Double-Blind Method; | 1996 |
The use of benzodiazepines in the treatment of manic-depressive illness.
Topics: Acute Disease; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Basal Ga | 1988 |
Antiemetic therapy in patients treated with high-dose cytosine arabinoside.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Cytarabine; Drug Therapy, | 1987 |
5 other studies available for lorazepam and Basal Ganglia Diseases
| Article | Year |
|---|---|
PANDAS with catatonia: a case report. Therapeutic response to lorazepam and plasmapheresis.
Topics: Attention Deficit Disorder with Hyperactivity; Autoimmune Diseases; Basal Ganglia Diseases; Catatoni | 2005 |
Neonatal extrapyramidal movements. Neonatal withdrawal due to maternal citalopram and ondansetron use.
Topics: Adult; Anti-Anxiety Agents; Basal Ganglia Diseases; Citalopram; Female; Humans; Infant, Newborn; Lor | 2008 |
Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics.
Topics: Adolescent; Adult; Age Factors; Aged; Antiparkinson Agents; Basal Ganglia Diseases; Drug Therapy, Co | 1982 |
Extrapyramidal reaction caused by ondansetron.
Topics: Adult; Basal Ganglia Diseases; Humans; Leukemia, Myeloid, Acute; Lorazepam; Male; Ondansetron | 1994 |
Neuroleptic malignant syndrome precipitated by promethazine and lorazepam.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Basal Ganglia Diseases; Histamine H1 Antagonists; | 2001 |